Eucrisa (crisaborole) / Pfizer 
Welcome,         Profile    Billing    Logout  
 11 Diseases   8 Trials   8 Trials   513 News 


12345678»
  • ||||||||||  Eucrisa (crisaborole) / Pfizer
    Review, Journal:  Recent Advances in Phytochemical-Based Topical Applications for the Management of Eczema: A Review. (Pubmed Central) -  May 25, 2024   
    This discussion delves into the efficacy of various nanocarriers, including liposomes, ethosomes, nanoemulsions, micelles, nanocrystals, solid-lipid nanoparticles, and polymeric nanoparticles. Consequently, the potential long-term side effects such as atrophy, eruptions, lymphoma, pain, and allergic reactions that are associated with current topical treatments, including emollients, topical corticosteroids, topical calcineurin inhibitors, and crisaborole, can potentially be mitigated through the use of phytochemical-based natural topical treatments.
  • ||||||||||  Eucrisa (crisaborole) / Pfizer
    Journal:  Efficacy and Safety of Crisaborole Ointment 2% in Chinese Patients Aged???2 Years with Mild to Moderate Atopic Dermatitis. (Pubmed Central) -  May 15, 2024   
    P3
    Consequently, the potential long-term side effects such as atrophy, eruptions, lymphoma, pain, and allergic reactions that are associated with current topical treatments, including emollients, topical corticosteroids, topical calcineurin inhibitors, and crisaborole, can potentially be mitigated through the use of phytochemical-based natural topical treatments. Crisaborole was effective and well tolerated in Chinese patients aged???2
  • ||||||||||  Eucrisa (crisaborole) / Pfizer
    Allergic Contact Dermatitis in the Era of Glycemic Control Devices: Unveiling Sensitizing Allergens and Boosting Device Tolerance via Immunomodulation (Palma) -  Apr 5, 2024 - Abstract #EAACI2024EAACI_808;    
    The intervention phase involved preemptive application of topical treatments with either a phosphodiesterase-4 inhibitor (Crisaborole) or a calcineurin inhibitor (Tacrolimus) to the sites of the incident before re-exposure to the diabetes devices...Conclusion The findings highlight the restricted effectiveness of "original device adhesive patch testing" and underscore the importance of individualized allergen-focused assessments for customizing diabetes device selection. The positive response to the immunomodulatory treatment suggests the onset of a new therapeutic approach, considering the efficacy of device replacement as a solution, the high cost and limited availability of alternative devices for glycemic control.
  • ||||||||||  Eucrisa (crisaborole) / Pfizer
    Journal:  A case of plasma cell vulvitis successfully treated with crisaborole. (Pubmed Central) -  Apr 1, 2024   
    In this regard, AD requires a united approach between clinicians, researchers, affected individuals, and policymakers to refine patient-focused treatment and develop precise, economical strategies to address this chronic and frequently life-altering health condition. No abstract available
  • ||||||||||  Eucrisa (crisaborole) / Pfizer, Kerydin (tavaborole) / Pfizer
    Journal:  Design, Synthesis, and Antifungal Activity of 3-Substituted-2(5H)-Oxaboroles. (Pubmed Central) -  Mar 20, 2024   
    These oxaboroles were nonhemolytic and nontoxic to rat myoblast cells (H9c2). Structure-activity relationship studies suggest that planarity is important for antimicrobial activity, possibly due to the effects of extended conjugation between the oxaborole and benzene rings.
  • ||||||||||  Dupixent (dupilumab) / Sanofi, Regeneron
    Comparing real-world effectiveness and adverse effects of oral JAK inhibitors versus dupilumab in patients with atopic dermatitis: A population-based cohort study () -  Feb 20, 2024 - Abstract #AAD2024AAD_2676;    
    Patients aged 18 years or older with AD who initiated treatment with either oral JAKi (abrocitinib, baricitinib, or upadacitinib) or dupilumab were included...Those who initiated JAKi treatment presented with significantly less subsequent use of topical agents (including high-potency topical corticosteroids, calcineurin inhibitors, and crisaborole) (hazard ratio (HR), 0.86; 95% confidence interval (CI), 0.75-0.98), and atopic comorbidities (HR, 0.66; 95% CI, 0.54-0.80), including asthma (HR, 0.62; 95% CI, 0.48-0.79), allergic rhinitis (HR, 0.70; 95% CI, 0.54-0.91), and conjunctivitis (HR, 0.46; 95% CI, 0.29-0.73). These findings suggest that oral JAKi demonstrate better disease control than dupilumab and are well-tolerated for AD treatment.
  • ||||||||||  Eucrisa (crisaborole) / Pfizer, Daliresp (roflumilast) / AstraZeneca, Takeda, AbbVie
    Clinical, Review, Journal:  Phosphodiesterase-4 Inhibition in the Management of Psoriasis. (Pubmed Central) -  Jan 23, 2024   
    This review summarizes evidence from randomized clinical trials regarding the efficacy and safety of PDE4 inhibitors in psoriasis treatment. By highlighting their potential benefits and limitations, this review provides valuable insights for clinicians and researchers aiming to optimize psoriasis management.
  • ||||||||||  PF-07038124 / Pfizer, Eucrisa (crisaborole) / Pfizer
    Trial completion date, Trial primary completion date:  Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo (clinicaltrials.gov) -  Nov 8, 2023   
    P2a,  N=64, Recruiting, 
    Still, these findings have to be corroborated by controlled studies with human patients in the future. Trial completion date: Jul 2023 --> Dec 2024 | Trial primary completion date: Jul 2023 --> Nov 2024
  • ||||||||||  Eucrisa (crisaborole) / Pfizer
    Trial completion:  Wearable Skin Sensors to Assess Nocturnal Scratch Behavior (clinicaltrials.gov) -  Oct 13, 2023   
    P=N/A,  N=23, Completed, 
    No abstract available Active, not recruiting --> Completed
  • ||||||||||  Eucrisa (crisaborole) / Pfizer
    PK/PD data, Preclinical, Journal:  Confocal Raman Spectroscopic Characterization of Dermatopharmacokinetics Ex Vivo. (Pubmed Central) -  Oct 6, 2023   
    Metrics related to local bioavailability (and potentially bioequivalence) included areas under the normalized C?N signal versus depth profiles and elimination rate constants deduced post-removal of the formulations. Finally, Raman measurements were made with an approved dermatological drug, crisaborole, for which delivery from a fully saturated formulation into the skin layers just below the SC was detectable.
  • ||||||||||  Eucrisa (crisaborole) / Pfizer, acoziborole (SCYX-7158) / SCYNEXIS
    Review, Journal:  Elemental exchange: Bioisosteric replacement of phosphorus by boron in drug design. (Pubmed Central) -  Sep 18, 2023   
    Although boron phosphate-mimetic molecules - FDA-approved Crisaborole and phase II/III clinical candidate Acoziborole are products of the boron-phosphorus bioisosteric elemental exchange strategy, this technique is still in its infancy. The review aims to promote the use of this strategy in future medicinal chemistry projects.
  • ||||||||||  Dupixent (dupilumab) / Sanofi, Regeneron
    A Case of Erythema Multiforme Following Dupilumab Administration in a Pediatric Atopic Dermatitis Patient (Monitor 02) -  Sep 14, 2023 - Abstract #ACAAI2023ACAAI_571;    
    Dupilumab is a relatively new treatment option for eczema, with approval in young children coming in June 2022. While erythema multiforme is listed on the package insert as a possible adverse effect, it is very uncommon, illustrating the importance of continued vigilant observation, especially with new medications.
  • ||||||||||  Eucrisa (crisaborole) / Pfizer
    Preclinical, Journal:  Crisaborole Inhibits Itch and Pain by Preventing Neutrophil Infiltration in a Mouse Model of Atopic Dermatitis. (Pubmed Central) -  Aug 26, 2023   
    Calcium imaging of mouse dorsal root ganglion neurones revealed that pretreatment with S100A8/A9 significantly increased calcium responses to histamine and capsaicin, and the proportion of chloroquine-sensitive neurones. These findings suggest that the PDE4 inhibitor reduces itch and pain, in part by inhibiting infiltration of S100A8/A9-containing neutrophils in a mouse model of MC903-induced atopic dermatitis.
  • ||||||||||  Eucrisa (crisaborole) / Pfizer
    Preclinical, Journal:  Crisaborole Loaded Nanoemulgel for the Mitigation of Atopic Dermatitis in Mice Model. (Pubmed Central) -  Aug 24, 2023   
    In vivo studies demonstrated that the nanoemulgel provided better therapeutic effect than the ointment. We can thereby conclude that nanoemulgel formulation can be a successful drug delivery strategy for enhancing the therapeutic effect of CB.
  • ||||||||||  Eucrisa (crisaborole) / Pfizer
    Trial completion date, Adherence:  Eucrisa for Atopic Dermatitis (clinicaltrials.gov) -  Aug 1, 2023   
    P1,  N=28, Active, not recruiting, 
    We can thereby conclude that nanoemulgel formulation can be a successful drug delivery strategy for enhancing the therapeutic effect of CB. Trial completion date: Jul 2023 --> Dec 2023
  • ||||||||||  Eucrisa (crisaborole) / Pfizer
    Enrollment change, Adherence:  Eucrisa for Atopic Dermatitis (clinicaltrials.gov) -  Jul 3, 2023   
    P1,  N=28, Active, not recruiting, 
    No abstract available N=40 --> 28
  • ||||||||||  What () -  Jul 3, 2023 - Abstract #WCD2023WCD_5896;    
    There are multiple new treatments on the horizon for AA. Our review focuses on recent clinical trials for this condition and highlights what is to come as far as new and emerging treatments
  • ||||||||||  clobetasol propionate topical / Generic mfg.
    Comparison of Effectiveness of Topical Treatments for Atopic Dermatitis () -  Jun 19, 2023 - Abstract #RAD2023RAD_109;    
    There is a lack of head-to-head trials for topical treatments for AD. Due to the tremendous burden of AD on patients' physical and mental health, there is a need for additional therapies.
  • ||||||||||  lirentelimab (AK002) / Allakos
    Phase 2 Trial in Progress () -  Jun 19, 2023 - Abstract #RAD2023RAD_75;    
    P2
    Due to the tremendous burden of AD on patients' physical and mental health, there is a need for additional therapies. The results of these studies provide a strong rationale for conducting this phase 2 proof-of-concept, randomized, double-blind, placebo-controlled study of lirentelimab SC in adults with moderate
  • ||||||||||  Moizerto (difamilast) / Otsuka, Medimetriks
    Journal:  Pharmacological Profile of Difamilast, a Novel Selective Phosphodiesterase 4 Inhibitor, for the Topical Treatment of Atopic Dermatitis. (Pubmed Central) -  Jun 19, 2023   
    Significance Statement This is the first report on the nonclinical pharmacological profile of difamilast ointment, a novel topical PDE4 inhibitor that demonstrated utility in clinical trials in patients with atopic dermatitis. Difamilast, which has high PDE4 selectivity (especially for the PDE4B subtype), ameliorated chronic allergic contact dermatitis in mice after topical application, with a pharmacokinetic profile in animals that suggests few systemic side effects; thus, difamilast is a promising new therapeutic treatment for atopic dermatitis.
  • ||||||||||  Eucrisa (crisaborole) / Pfizer
    Enrollment closed:  Steroid-reducing Effects of Crisaborole (clinicaltrials.gov) -  Jun 9, 2023   
    P4,  N=60, Active, not recruiting, 
    Difamilast, which has high PDE4 selectivity (especially for the PDE4B subtype), ameliorated chronic allergic contact dermatitis in mice after topical application, with a pharmacokinetic profile in animals that suggests few systemic side effects; thus, difamilast is a promising new therapeutic treatment for atopic dermatitis. Recruiting --> Active, not recruiting